The new data presented by Novartis at ECTRIMS 2022 highlighted ... slow down the progression of the disease. Kesimpta is such a drug, taken as an injection under the skin once a month.

Novartis has secured backing from NICE for its relapsing multiple sclerosis (RMS) therapy Kesimpta in the UK, just two weeks after the drug was approved by the national drugs regulator.

Novartis' key drivers were Entresto, Kisqali, Kesimpta, and Sandostatin (Fig 2), offsetting Cosentyx and Zolgensma's weak performance. Going down in the P&L analysis, the company's operating costs ...

When giving gluteal injections, it is safest to use the upper outer quadrant. The choice of site for injection must be based on good clinical judgment, using the best evidence available and ...

A family leisure chain in Somerset has become the first in the UK to install life-saving anaphylactic auto-injectors across all three of its indoor play centres. The equipment, which has been ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.